EP1774012A2 - Immune modulating compounds from fungi - Google Patents
Immune modulating compounds from fungiInfo
- Publication number
- EP1774012A2 EP1774012A2 EP05758000A EP05758000A EP1774012A2 EP 1774012 A2 EP1774012 A2 EP 1774012A2 EP 05758000 A EP05758000 A EP 05758000A EP 05758000 A EP05758000 A EP 05758000A EP 1774012 A2 EP1774012 A2 EP 1774012A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- composition according
- polysaccharides
- glucose
- mannose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000233866 Fungi Species 0.000 title claims abstract description 44
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 title description 16
- 239000000203 mixture Substances 0.000 claims abstract description 256
- 150000004676 glycans Chemical class 0.000 claims abstract description 131
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 131
- 239000005017 polysaccharide Substances 0.000 claims abstract description 131
- 238000011282 treatment Methods 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 48
- 239000007788 liquid Substances 0.000 claims abstract description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- 229920001184 polypeptide Polymers 0.000 claims abstract description 34
- 230000001010 compromised effect Effects 0.000 claims abstract description 18
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 73
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 72
- 239000008103 glucose Substances 0.000 claims description 72
- 229930182830 galactose Natural products 0.000 claims description 66
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 64
- 150000002772 monosaccharides Chemical class 0.000 claims description 44
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 37
- 239000001963 growth medium Substances 0.000 claims description 30
- 241000222418 Lentinus Species 0.000 claims description 24
- 240000000599 Lentinula edodes Species 0.000 claims description 23
- 230000002538 fungal effect Effects 0.000 claims description 22
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 20
- 238000000108 ultra-filtration Methods 0.000 claims description 15
- 238000001471 micro-filtration Methods 0.000 claims description 13
- 108010002352 Interleukin-1 Proteins 0.000 claims description 11
- 238000002523 gelfiltration Methods 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 210000000987 immune system Anatomy 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 241001327634 Agaricus blazei Species 0.000 claims description 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 8
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 8
- 240000008397 Ganoderma lucidum Species 0.000 claims description 8
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 230000016784 immunoglobulin production Effects 0.000 claims description 7
- 238000005199 ultracentrifugation Methods 0.000 claims description 7
- 206010019799 Hepatitis viral Diseases 0.000 claims description 6
- 241000222354 Trametes Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 230000018276 interleukin-1 production Effects 0.000 claims description 6
- 208000022218 streptococcal pneumonia Diseases 0.000 claims description 6
- 201000001862 viral hepatitis Diseases 0.000 claims description 6
- 244000251953 Agaricus brunnescens Species 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 244000045069 Agrocybe aegerita Species 0.000 claims description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 241000222356 Coriolus Species 0.000 claims description 4
- 235000016640 Flammulina velutipes Nutrition 0.000 claims description 4
- 240000006499 Flammulina velutipes Species 0.000 claims description 4
- 235000007710 Grifola frondosa Nutrition 0.000 claims description 4
- 240000001080 Grifola frondosa Species 0.000 claims description 4
- 241000606768 Haemophilus influenzae Species 0.000 claims description 4
- 206010027241 Meningitis haemophilus Diseases 0.000 claims description 4
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims description 4
- 206010027255 Meningitis staphylococcal Diseases 0.000 claims description 4
- 206010027256 Meningitis streptococcal Diseases 0.000 claims description 4
- 206010028851 Necrosis Diseases 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 235000007685 Pleurotus columbinus Nutrition 0.000 claims description 4
- 240000001462 Pleurotus ostreatus Species 0.000 claims description 4
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims description 4
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 claims description 4
- 206010035728 Pneumonia pneumococcal Diseases 0.000 claims description 4
- 206010035737 Pneumonia viral Diseases 0.000 claims description 4
- 241000222481 Schizophyllum commune Species 0.000 claims description 4
- 241001558929 Sclerotium <basidiomycota> Species 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 241000908178 Tremella fuciformis Species 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 201000005008 bacterial sepsis Diseases 0.000 claims description 4
- 206010014599 encephalitis Diseases 0.000 claims description 4
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 4
- 208000010523 haemophilus meningitis Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 208000004593 pneumococcal meningitis Diseases 0.000 claims description 4
- 201000001739 streptococcal meningitis Diseases 0.000 claims description 4
- 208000009421 viral pneumonia Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000000099 in vitro assay Methods 0.000 claims description 3
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 208000010920 Actinomycetales infectious disease Diseases 0.000 claims description 2
- 235000008121 Agrocybe aegerita Nutrition 0.000 claims description 2
- 241001199091 Albatrellus confluens Species 0.000 claims description 2
- 241000502227 Arrhenia epichysium Species 0.000 claims description 2
- 201000002909 Aspergillosis Diseases 0.000 claims description 2
- 208000036641 Aspergillus infections Diseases 0.000 claims description 2
- 240000005710 Auricularia polytricha Species 0.000 claims description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims description 2
- 201000004813 Bronchopneumonia Diseases 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 201000006082 Chickenpox Diseases 0.000 claims description 2
- 241001185363 Chlamydiae Species 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims description 2
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 claims description 2
- 241000193163 Clostridioides difficile Species 0.000 claims description 2
- 241000222680 Collybia Species 0.000 claims description 2
- 241000709687 Coxsackievirus Species 0.000 claims description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 201000007336 Cryptococcosis Diseases 0.000 claims description 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010012742 Diarrhoea infectious Diseases 0.000 claims description 2
- 206010014612 Encephalitis viral Diseases 0.000 claims description 2
- 241000123150 Fomitopsis pinicola Species 0.000 claims description 2
- 241001149422 Ganoderma applanatum Species 0.000 claims description 2
- 241001480597 Ganoderma tsugae Species 0.000 claims description 2
- 201000000628 Gas Gangrene Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 206010061166 Gastroenteritis bacterial Diseases 0.000 claims description 2
- 206010017918 Gastroenteritis viral Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 240000000588 Hericium erinaceus Species 0.000 claims description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 201000002563 Histoplasmosis Diseases 0.000 claims description 2
- 241001534815 Hypsizygus marmoreus Species 0.000 claims description 2
- 201000008225 Klebsiella pneumonia Diseases 0.000 claims description 2
- 241000222689 Laetiporus Species 0.000 claims description 2
- 241000222635 Lenzites betulinus Species 0.000 claims description 2
- 206010024641 Listeriosis Diseases 0.000 claims description 2
- 206010024652 Liver abscess Diseases 0.000 claims description 2
- 241000218554 Lyophyllum Species 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010027260 Meningitis viral Diseases 0.000 claims description 2
- 241000993286 Mucidula mucida Species 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 206010034107 Pasteurella infections Diseases 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 235000014528 Pholiota nameko Nutrition 0.000 claims description 2
- 244000168667 Pholiota nameko Species 0.000 claims description 2
- 241000123196 Piptoporus betulinus Species 0.000 claims description 2
- 241000392443 Pleurotus citrinopileatus Species 0.000 claims description 2
- 241001138370 Pleurotus pulmonarius Species 0.000 claims description 2
- 206010054047 Pneumococcal sepsis Diseases 0.000 claims description 2
- 241000233872 Pneumocystis carinii Species 0.000 claims description 2
- 206010035665 Pneumonia adenoviral Diseases 0.000 claims description 2
- 206010060946 Pneumonia bacterial Diseases 0.000 claims description 2
- 206010035717 Pneumonia klebsiella Diseases 0.000 claims description 2
- 206010035727 Pneumonia parainfluenzae viral Diseases 0.000 claims description 2
- 208000033398 Pneumonia pseudomonas aeruginosa Diseases 0.000 claims description 2
- 206010035732 Pneumonia respiratory syncytial viral Diseases 0.000 claims description 2
- 206010035734 Pneumonia staphylococcal Diseases 0.000 claims description 2
- 206010035735 Pneumonia streptococcal Diseases 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 241001556152 Porodaedalea pini Species 0.000 claims description 2
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000123160 Sarcomyxa serotina Species 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 206010040550 Shigella infections Diseases 0.000 claims description 2
- 206010041047 Slow virus infection Diseases 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 206010042254 Strongyloidiasis Diseases 0.000 claims description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 2
- 241000001727 Tropicoporus linteus Species 0.000 claims description 2
- 206010046980 Varicella Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 240000006794 Volvariella volvacea Species 0.000 claims description 2
- 235000004501 Volvariella volvacea Nutrition 0.000 claims description 2
- 241001619444 Wolfiporia cocos Species 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims description 2
- 201000007691 actinomycosis Diseases 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 208000001848 dysentery Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 claims description 2
- 230000002956 necrotizing effect Effects 0.000 claims description 2
- 230000024241 parasitism Effects 0.000 claims description 2
- 201000005115 pasteurellosis Diseases 0.000 claims description 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 201000005113 shigellosis Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 208000006379 syphilis Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 201000002498 viral encephalitis Diseases 0.000 claims description 2
- 244000221226 Armillaria mellea Species 0.000 claims 1
- 235000011569 Armillaria mellea Nutrition 0.000 claims 1
- 235000000024 Auricularia polytricha Nutrition 0.000 claims 1
- 241000123326 Fomes Species 0.000 claims 1
- 239000000047 product Substances 0.000 description 115
- 238000007912 intraperitoneal administration Methods 0.000 description 41
- 235000013376 functional food Nutrition 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 239000002158 endotoxin Substances 0.000 description 31
- 229920006008 lipopolysaccharide Polymers 0.000 description 31
- 238000004519 manufacturing process Methods 0.000 description 29
- 238000003556 assay Methods 0.000 description 25
- 235000008429 bread Nutrition 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 239000002609 medium Substances 0.000 description 20
- 210000004988 splenocyte Anatomy 0.000 description 17
- 235000013365 dairy product Nutrition 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 235000013351 cheese Nutrition 0.000 description 15
- 238000000855 fermentation Methods 0.000 description 15
- 230000004151 fermentation Effects 0.000 description 15
- 238000005194 fractionation Methods 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 229920001491 Lentinan Polymers 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 14
- 230000036541 health Effects 0.000 description 14
- 229940115286 lentinan Drugs 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- 235000013618 yogurt Nutrition 0.000 description 13
- 231100000822 oral exposure Toxicity 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 239000002028 Biomass Substances 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000007928 intraperitoneal injection Substances 0.000 description 11
- 102000000589 Interleukin-1 Human genes 0.000 description 10
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000017306 interleukin-6 production Effects 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 238000007427 paired t-test Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 235000015243 ice cream Nutrition 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 8
- 210000000416 exudates and transudate Anatomy 0.000 description 8
- 235000015203 fruit juice Nutrition 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 230000006433 tumor necrosis factor production Effects 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 108010062580 Concanavalin A Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 230000019189 interleukin-1 beta production Effects 0.000 description 6
- 235000004213 low-fat Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000011888 snacks Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 235000008924 yoghurt drink Nutrition 0.000 description 6
- 244000099147 Ananas comosus Species 0.000 description 5
- 235000007119 Ananas comosus Nutrition 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000012465 retentate Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- 235000009854 Cucurbita moschata Nutrition 0.000 description 4
- 240000001980 Cucurbita pepo Species 0.000 description 4
- 235000009852 Cucurbita pepo Nutrition 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 241000123167 Lentinellus ursinus Species 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 244000078534 Vaccinium myrtillus Species 0.000 description 4
- 240000006365 Vitis vinifera Species 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 235000015142 cultured sour cream Nutrition 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000019734 interleukin-12 production Effects 0.000 description 4
- 229940047122 interleukins Drugs 0.000 description 4
- 235000015141 kefir Nutrition 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 235000020166 milkshake Nutrition 0.000 description 4
- 235000012459 muffins Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000020354 squash Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001558184 Agaricus sp. Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241001672694 Citrus reticulata Species 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- 240000009088 Fragaria x ananassa Species 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- 235000011430 Malus pumila Nutrition 0.000 description 3
- 235000015103 Malus silvestris Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 235000009827 Prunus armeniaca Nutrition 0.000 description 3
- 244000018633 Prunus armeniaca Species 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000012970 cakes Nutrition 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000014505 dips Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 235000011868 grain product Nutrition 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000012771 pancakes Nutrition 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000004730 pulsed amperometry Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000012773 waffles Nutrition 0.000 description 3
- 241000222518 Agaricus Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 240000006063 Averrhoa carambola Species 0.000 description 2
- 235000010082 Averrhoa carambola Nutrition 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 235000004936 Bromus mango Nutrition 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 235000001427 Cylindropuntia imbricata Nutrition 0.000 description 2
- 240000005729 Cylindropuntia imbricata Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- -1 IL-1β Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 244000162269 Lentinus lepideus Species 0.000 description 2
- 235000017066 Lentinus lepideus Nutrition 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 235000014826 Mangifera indica Nutrition 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000234295 Musa Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 235000000370 Passiflora edulis Nutrition 0.000 description 2
- 244000288157 Passiflora edulis Species 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 240000001987 Pyrus communis Species 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000009184 Spondias indica Nutrition 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000012791 bagels Nutrition 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 235000021029 blackberry Nutrition 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 235000015496 breakfast cereal Nutrition 0.000 description 2
- 235000012802 brown bread Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000012495 crackers Nutrition 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000015071 dressings Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000014168 granola/muesli bars Nutrition 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000010746 mayonnaise Nutrition 0.000 description 2
- 239000008268 mayonnaise Substances 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000012830 plain croissants Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000011962 puddings Nutrition 0.000 description 2
- 235000021013 raspberries Nutrition 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 235000021012 strawberries Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000012184 tortilla Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 235000012794 white bread Nutrition 0.000 description 2
- 235000012799 wholemeal bread Nutrition 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 240000007440 Agaricus campestris Species 0.000 description 1
- 235000008754 Agave americana Nutrition 0.000 description 1
- 240000004246 Agave americana Species 0.000 description 1
- 241000249058 Anthracothorax Species 0.000 description 1
- 240000001913 Atriplex hortensis Species 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000131482 Bifidobacterium sp. Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241001237231 Cyptotrama asprata Species 0.000 description 1
- 241000701482 Cyptotrama chrysopepla Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000472351 Echinopsis aurea Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000123330 Fomes fomentarius Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 description 1
- 229920002324 Galactoglucomannan Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 240000005926 Hamelia patens Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000134337 Lentinellus novae-zelandiae Species 0.000 description 1
- 241000134340 Lentinellus pulvinulus Species 0.000 description 1
- 241000136543 Lentinus badius Species 0.000 description 1
- 241001536575 Lentinus concinnus Species 0.000 description 1
- 241000222465 Lentinus strigosus Species 0.000 description 1
- 241000149440 Lentinus tuber-regium Species 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241001480581 Marasmius Species 0.000 description 1
- 241001576503 Mellea Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102000002247 NADPH Dehydrogenase Human genes 0.000 description 1
- 108010014870 NADPH Dehydrogenase Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000947860 Pasteurellales Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 244000158441 Pleurotus sajor caju Species 0.000 description 1
- 235000004116 Pleurotus sajor caju Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006029 Prunus persica var nucipersica Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000017714 Prunus persica var. nucipersica Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000234524 Rhodocybe Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 235000016911 Ribes sativum Nutrition 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 235000016897 Ribes triste Nutrition 0.000 description 1
- 244000281209 Ribes triste Species 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000012411 boiled sweets Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 235000012180 bread and bread product Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009264 composting Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 235000012777 crisp bread Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000019221 dark chocolate Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000012779 flatbread Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000012490 fresh bread Nutrition 0.000 description 1
- 235000008410 fruit bars Nutrition 0.000 description 1
- 235000013572 fruit purees Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000011617 hard cheese Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015145 nougat Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000012780 rye bread Nutrition 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000008983 soft cheese Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 235000011845 white flour Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to immune modulating compounds comprising polysaccharides that may be isolated from a liquid culture of fungi.
- lentinan a polysaccharide based compound described as a beta-(1,3) glucan backbone with beta-(1 ,6) side chains.
- Solid-state reactors are routinely used for culturing fungi such as Lentinus edodes. This is a technology which is used for many purposes such as composting, production of biological products such as enzymes, soy sauce, acetic acid, and the like.
- lentinan - Lentinus edodes.
- the fruiting bodies are harvested, either by hand or mechanically, and are subsequently dried and ground to a powder which can be used as it is, or used in tablets, or sent for further processing such as extraction of lentinan.
- a polysaccharide product prepared from Lentinus edode is commercially available as "Lentinan for injection” (Eureka Bio-Chemicals Pty, Australia). This product has some immunestimulating effect (see also the examples herein below).
- compositions with very high immunestimulating activity have not been disclosed. It is therefore an object of the present invention to provide novel compostions, preferably extracellular immune stimulating agents from fungi with high level of immune modulating activity.
- the present invention discloses compositions comprising polysaccharides with significant immune modulating activity. Interestingly, the present invention discloses that the specific monosaccharide content of a polysaccharide composition is important for the immune modulating activity.
- a composition comprising one or more polypeptides and a mixture of polysaccharides, wherein the majority of the polysaccharides of the composition, preferably every polysaccharide has a molecular weight of at least 10,000 Da and wherein said mixture of polysaccharides comprises the monosaccharides galactose, mannose, and glucose in the ratio (0- 1.5) : (0-0.5) to (15-35) : (0.5-1.5) to (45-55), preferably in the ratio of about 1 :0 to 25:1 to 50, such as in the ration of 1 :0 to 25:1 to.50.
- a composition comprising one or more polypeptides and a mixture of polysaccharides, wherein: a) the majority of the polysaccharides of the composition have a molecular weight of at least 30,000 Da and wherein said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 1 :0 to 25:1 to 50, or b) the majority of the polysaccharides of the composition have a molecular weight of at least 100,000 Da and wherein said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 0 to 0.5:0.5 to 10:0.5 to 50, or c) the majority of the polysaccharides of the composition have a molecular weight of at least 1 ,000 Da and wherein said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 1 :0 to 25:1 to 50.
- compositions according to the invention in the manufacture of a medicament for treatment, optionally prophylactic treatment of an immune compromised condition of an individual in need of such treatment.
- Polysaccharides covers polysaccharides as well as polysaccharides containing and/or covalently linked to peptides, polypeptides or the like, such as proteopolysaccharides.
- Polysaccharides comprising monosaccharides A polysaccharide is said to comprise monosaccharides, wherein said monosaccharides are covalently linked to form said polysaccharide. Hydrolysing a polysaccharide will yield the monosaccharides that formed said polysaccharide in free form.
- the monosaccharide content of a polysaccharide can thus be determined by hydrolysing the polysaccharide and measuring the presence of individual monosaccharides.
- the monosaccharide content of a mixture of polysaccharides is determined by determining the monosaccharide content of the entire mixture.
- a polysaccharide or a mixture of polysaccharides are said to comprise galactose, mannose, and glucose in a given ratio, when hydrolysation of said polysaccharide or said mixture of polysaccharide yields galactose, mannose and glucose in said given ratio.
- Galactose, mannose, and glucose in the ratio 1 :a to b:c to d means that for every part galactose, mannose is present in the range of a to b parts and glucose is present in the range of c to d parts, wherein a, b, c and d indicates numerical values.
- a polysaccharide mixture comprising galactose, mannose, and glucose in the ratio 1:5 to 25:1 to 50, means that for every part galactose, the polysaccharide mixture comprises in the range of 5 to 25 parts mannose and in the range if 1 to 50 part glucose.
- Molecular weight Every polysaccharide of a composition is said to have a molecular weight of at least a given value, when said composition has been purified using a filtration step resulting in a molecular weight cut-off of said given value.
- every polysaccharide of a composition is said to have a molecular weight within a given range, when said composition has been subjected to one or more filtration steps resulting in a lower molecular weight cut-off which is the lower value of the range and an upper molecular weight cut-off which is the upper value of the range.
- Said filtration step may for example be ultrafiltration, microfiltration, ultracentrifugation or gel filtration.
- a composition wherein every polysaccharide has a molecular weight of at least a given value or every polysaccharide is said to have a molecular weight within a given range may also be prepared by other methods.
- Polypeptide covers proteins, peptides and polypeptides, wherein said proteins, peptides or polypeptides may or may not have been post-translationally modified. Post-translational modification may for example be phosphorylation, methylation, glucosylation.
- compositions according to the present invention comprise one or more polypeptides and a mixture of polysaccharides.
- Said polypeptides may optionally be covalently linked to polysaccharides. It is however also comprised within the present invention that said polypeptides are either not associated with said polysaccharides or that said polypeptides are associated with said polysaccharides in a non-covalent manner.
- compositions comprise polysaccharides which may or may not be proteopolysaccharides, or the compositions may comprise a mixture of both.
- the compositions according to the present invention are isolated or purified compositions, i.e. they have been subjected to one or more purification steps. In a preferred embodiment they have been purified from liquid growth medium of a fungal mycelium using at least one purification step comprising a size fractionation. Methods of purification are described in more detail below.
- the composition essentially consists of polysaccharides and optionally polypeptides,-more preferably the composition essentially consists of polysaccharides and polypeptides.
- the composition is a liquid composition, and it is then preferred that the composition essentially consists of polysaccharides and optionally polypeptides dissolved in an aqueous solution optionally comprising salts and buffer.
- the polysaccharides of the compositions of the invention preferably comprises the monosaccharides glucose, mannose and galactose.
- polysaccharides and polypeptides that may be comprised within the compositions of the invention include, but are not limited to, ⁇ -(1 ,3), ⁇ -(1 ,6) D-glucans, schizophyllan, grifolan, coriolan and Coriolus versicolor glycosylated polypeptides such as PSK and PSP, polypeptides associated with alpha-mannan such as KS-2, which may be isolated from Lentinus edodes, and reishi, which may be isolated from Ganoderma lucidum; glucuronoxylomannans; mannoglucans; glucomannans; galactoglucan and/or galactoglucomannans.
- compositions disclosed herein have been produced by a fungus.
- the compositions have been purified from the extracellular environment of a fungus.
- the fungus preferably a fungal mycelium, has been cultivated in a liquid growth medium and said composition has been purified from said liquid growth medium.
- composition of the invention has been produced by a method comprising the steps of i) cultivating a fungus, such as a fungal mycelium, in a liquid growth medium, and ii) isolating the composition from said liquid growth medium
- fungal mycelium any fungal biomass, which can be grown in a submerged culture.
- the fungal biomass may be in the form of single hyphae, spores, aggregates of mycelium, and partly differentiated mycelium.
- the liquid growth medium may be any of the liquid growth media described herein below.
- the fungus may be any fungus, preferably a fungus forming a fungal mycelium, more preferably the fungus is a filamentous fungus. Even more preferably, the fungus may be selected from the group consisting of Agaricus bisporus, Cordiceps sinensis, Flammulina velutipes, Ganoderma lucidum, Grifola frondosa, Lentinus edodes, Pleurotus ostreatus, Schizophyllum commune, Sclerotina sclerotium, Trametes (Coriolus) versicolor, Tremella fuciformis, Agaricus blazei, Agrocybe aegerita, Agrocybe cylindracea, Albatrellus confluens, Armilla ⁇ ella mellea, Au ⁇ cula ⁇ a au ⁇ cula-judae, Auricularia polytrichia, Collybia maracula, Cordiceps militari, Dendrop
- Ganoderma applanatum Ganoderma tsugae, Hericium erinaceus, Hypsizygus marmoreus, lnonotus obliquus, Laetiporus sulphurous, Lenzites betulinus, Leucopaxilllus giganteus, Lyophyllum cinerascens, Omphalina epichysium, Oudemansiella mucida, Panellus serotinus, Piptoporus betulinus, Phellinus linteus, Phellinus pini, Pholiota nameko, Pleurotus citrinopileatus, Pleurotus pulmonarius, Sarcedon asparatus, Trametes suavolens, Volvariella volvacea and Wolfiporia cocos.
- the fungus is selected from the group consisting of Agaricus bisporus, Cordiceps sinensis, Flammulina velutipes, Ganoderma lucidum, Grifola frondosa, Lentinus edodes, Pleurotus ostreatus, Schizophyllum commune, Sclerotina sclerotium, Trametes (Coriolus) versicolor and Tremella fuciformis
- the fungus is Agaricus blazei.
- said fungus is Ganoderma, such as Ganoderma lucidum.
- the fungus is an Agaricus fungus, such as selected from the group consisting of: A. blazei, A. blazei Murill, A. bisporus, A. hortensis, A. campestris.
- the fungus belongs to the class of basidiomycetes, such as a fungus of the genus Lentinus, such as Lentinus edodes.
- Lentinus pygmaeus Colenso Lentinus zelandicus Sacc. & Cub. (1887); Lentinus sajor-caju (Fr.) Fr.; Lentinus squarrulosus Mont; Lentinus strigosus (Schwein.) Fr. (1825); Lentinus suffrutescens (Brot.) Fr. (1825); and Lentinus tuber-regium Fr.; Lentinus zelandicus Sacc. & Cub. (1887) (Ref: http://nzfungi . landcareresearch .co. nz) . Modulation of the immune system
- compositions according to the invention are preferably immune modulating, preferably, the compositions are immune stimulating.
- the stimulation of the immune system can be demonstrated by e.g. increased antibody production, by activation of helper T-cells, or by increased production of interleukins such as lnterleukin 1 and lnterleukin 2.
- any assay known to the skilled person, which is suitable for testing whether a composition is immune modulating may be employed to test whether a composition of the present invention is immune modulating.
- Such an assay may be an in vitro or an in vivo assay.
- the composition according to the present invention is capable of inducing IL-1 production from at least one kind of IL-1 producing cells in an in-vitro assay.
- the cells may be any IL-1 producing cells, such as P388 mouse macrophage cells.
- said cell is a IL-1 beta producing cell.
- IL-1 production may be determined using any suitable assay.
- assays involving the use of specific IL-1 antibodies, such as specific IL1- ⁇ and/or IL1- ⁇ antibodies are useful.
- Such assays may for example be Western blotting, ELISA or similar assays.
- the assay may be performed as described in example 4.
- the assay is preferably performed using a specific composition as reference.
- the composition is capable of inducing production of at least 1.5, preferably at least 2, such as at least 4, for example at least 6, such as at least 8, for example at least 10, such as at least 15, for example at least 20, such as at least 30, for example at least 40 times more IL1- ⁇ , than the amount of IL1- ⁇ induced using the commercially available Lentinan for injection (Eureka Bio-Chemicals Pty, Little Collins Street. Melbourne 3000, Australia) in a reference experiment performed in parallel..
- the composition is capable of inducing production of at least 1.5, preferably at least 2, such as at least 4, for example at least 6, such as at least 8, for example at least 10, such as at least 15, for example at least 20 times more IL1- ⁇ , than the amount of IL1- ⁇ induced using Lentinan for injection from Eureka Biochemicals Pty. in a reference experiment performed in parallel.
- the aforementioned assays are performed as described in example 4. It is most preferred that the composition induced production of both IL1 ⁇ and IL1 ⁇ as described above.
- the composition is capable of enhancing antibody production in a mammal, when administered to said mammal.
- the mammal may for example be a mouse, rat, rabbit or even a human being.
- an assay is performed by administering the composition to a mammal prior to and simultaneously with administration of an antigen, optionally in the presence of an adjuvant.
- the composition is administered in the range of 1 to 30 days, preferably in the range of 1 to 10 days, more preferably in the range of 1 to 3 days prior to administration of the antigen. Subsequently, antibody production in the mammal may be determined.
- the composition is preferably capable of inducing production of at least 1.5, more preferably at least 2, even more preferably at least 2.5, such as at least 3, for example at least 4, such as 6 times more antibody compared to the amount of antibody produced without administration of the composition.
- An example of such an assay is outlined in example 6.
- composition is immune modulating in more than one assay system, such as in a combination of any of the assay systems described herein above.
- compositions of the present invention act to increase TNF-alpha production, such as may be measured by the assay described in Example 9.
- composition according to the present invention preferably comprises polysaccharides, wherein the majority of the polysaccharides, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, yet more preferably at least 90%, even more preferably at least 95%, yet more preferably essentially all polysaccharides, most preferably every polysaccharide has a molecular weight above 10,000 Da, preferably above 30,000 Da, more preferably above 40,000 Da, even more preferably above 50,000 Da, for example at least 100,000 Da, such as at least 300,000 Da, for example at least 1,000,000 Da.
- the majority of polysaccharides preferably every polysaccharide of the composition has a molecular weight within the range of 10,000 to 3,000,000 Da., for example within the range of 30,000 to 3,000,000, such as within the range of 40,000 to 3,000,000, for example within the range of 50,000 to 3,000,000, such as in the range of 50,000 to 100,000, for example in the range of 100,000 to 300,000, such as in the range of 300,000, to 1,000,000, for example in the range of 1 ,000,000 to 3,000,000.
- the composition has been purified by a method involving at least one size fractionation step.
- the composition has been purified using at least one size fractionation step wherein molecules, such as polysaccharides with a nominal molecular weight above a given cut-off are separated from molecules, such as polysaccharides with a nominal molecular weight below said cut-off.
- molecules such as polysaccharides with a nominal molecular weight above a given cut-off are separated from molecules, such as polysaccharides with a nominal molecular weight below said cut-off.
- the size fractionation is ultrafiltration or microfiltration a membrane with said cut-off may be used.
- the size fractionation is gel filtration a gel with said molecular weight cut off may be chosen or a particular elution fraction may be used.
- the larger molecular weight fraction is used, wherein the cut-off preferably is 10,000 Da, more preferably 30,000 Da, even more preferably 40,000 Da, yet more preferably 50,000 Da.
- the composition has been purified by a method involving one or more size fractionation steps, wherein a resulting fraction comprises polysaccharides with a nominal molecular weight below a given cut-off and above a given cut-off.
- a resulting fraction comprises polysaccharides with a nominal molecular weight below a given cut-off and above a given cut-off.
- the size fractionation is ultrafiltration or microfiltration
- first one fractionation step using a membrane with the lower molecular weight cut off may be performed.
- the larger molecular weight fraction may be collected and subjected to a second ultrafiltration or microfiltration using a membrane with the upper molecular weight cut off.
- the lower molecular weight fraction may be collected.
- gel filtration a particular elution fraction may be used.
- ultracentrifugation is used, a membrane with the lower molecular cut-off and a membrane with the upper molecular weight cut-off may be used.
- composition according to the present invention comprises a mixture of polysaccharides, wherein said mixture comprises the monosaccharides galactose, mannose, and glucose in the ratio 1:5 to 25:1 to 50.
- the ratio reflects the ratio within the entire mixture of polysaccharides. It is thus feasible that each individual polysaccharide within the mixture comprises a different ratio of the monosaccharides.
- the ratio may in general be determined by degrading the entire mixture of polysaccharides into monosaccharides and subsequently determining the concentration of each of said monosaccharides.
- Polysaccharides may be degraded to their constituent monosaccharides by hydrolysis, for example by hydrolysis in a strong acid, such as HCI.
- the hydrolysate may be analysed by any conventional method available to the skilled person, for example by HPLC, mass spectrometry or NMR.
- polysaccharides comprise the mono ⁇ saccharides glucose and mannose. In another embodiment of the invention the polysaccharides comprise the monosaccharides glucose and galactose. In a preferred embodiment of the invention, the polysaccharides of the composition comprise the monosaccharides galactose, mannose and glucose.
- the mixture of polysaccharides comprises in the range of 5 to 25, preferably in the range of 5 to 20, more preferably in the range of 5 to 17, even more preferably in the range of 6 to 15, yet more preferably in the range of 7 to 14, such as in the range of 10 to 17, for example in the range of 11 to 16, such as in the range of 12 to 15, for example in the range of 13 to 14, such as approximately 13.4+/-0.4, for example 13.4+/-0.4 parts mannose for every part galactose.
- the mixture of polysaccharides comprises in the range of 1 to 50, preferably in the range of 1 to 40, more preferably in the range of 1 to 30, even more preferably in the range of 1 to 25, yet more preferably in the range of 1 to 20, even more preferably in the range of 2 to 15, yet more preferably in the range of 2 to 14, such as in the range of 8 to 17, for example in the range of 9 to 16, such as in the range of 10 to 15, for example in the range of 11 to 14, such as approximately 12.6+/-1.3, for example 12.6+/-1.3 parts glucose for every part galactose.
- the mixture comprises a ratio of mannose to galactose as indicated herein above and a ratio of glucose to galactose in a ratio as indicated herein above.
- the polysaccharides comprise mannose and glucose it is preferred that they comprise in the range of 0.1 to 30, such as in the range of 0.1 to 0.25, for example in the range of 0.25 to 0.5, such as in the range of 0.5 to .75, for example in the range of 0.75 to 1 , such as in the range of 1 to 5, for example in the range of 5 to 10, such in the range of 10 to 20, for example in the range of 20 to 30 parts glucose for every part mannose.
- the polysaccharides comprise in the range of 0.5 to 2 parts glucose for every part mannose, more preferably 13.4 +/-0.4 parts mannose 12.6 +/--1.3 part glucose.
- the composition comprises a mixture of polysaccharides comprises the monosacharides galactose, mannose, and glucose in the ratio 1:5 to 25:1 to 50, more preferably 1 :13.4 +/- 0.4:12.6 +/- 1.3.
- the composition comprises a mixture of polysaccharides, wherein the polysaccharides within said mixture having a molecular weight in the range of 50,000 to 100,000 comprises in the range of 3 to 15, preferably in the range of 4 to 14, more preferably in the range of 5 to 13, even more preferably in the range of 6 to 12, yet more preferably in the range of 7 to 11 , even more preferably in the range of 7.9 to 9.9, for example approximately 8.9 parts mannose for every part galactose.
- the polysaccharides having a molecular weight in the range of 50,000 to 100,000 comprises in the range of 1 to 5, preferably in the range of 2 to 4, even more preferably in the range of 2.5 to 3.5, such as approximately 2.9 parts glucose for every part galactose. It is preferred that the polysaccharides of said composition having a molecular weight in the range of 50,000 to 100,000 Da comprise the monosacharides galactose, mannose, and glucose in the ratio 1:4 to 14:1 to 5, preferably the ratio is approximately 1 :8.9:2.9.
- the composition comprises a mixture of polysaccharides, wherein the polysaccharides within said mixture having a molecular weight in the range of 100,000 to 300,000 comprises in the range of 3 to 15, preferably in the range of 3 to 14, more preferably in the range of 3 to 13, even more preferably in the range of 3 to 12, yet more preferably in the range of 4 to 11 , even more preferably in the range of 5 to 10, yet more preferably in the range of 6.3 to 8.3, for example approximately 7.3 parts mannose for every part galactose.
- the polysaccharides having a molecular weight in the range of 100,000 to 300,000 comprises in the range of 1 to 5, preferably in the range of 2 to 4, even more preferably in the range of 2.5 to 3.5, such as approximately 2.9 parts glucose for every part galactose. It is preferred that the polysaccharides of said composition having a molecular weight in the range of 50,000 to 100,000 Da comprise the monosacharides galactose, mannose, and glucose in the ratio 1 :3 to 13:1 to 5, preferably the ratio is approximately 1 :7.3:2.9.
- the composition comprises a mixture of polysaccharides, wherein the polysaccharides within said mixture having a molecular weight in the range of 300,000 to 1 ,000,000 comprises in the range of 3 to 16, preferably in the range of 5 to 15, more preferably in the range of 5 to 14, even more preferably in the range of 6 to 13, yet more preferably in the range of 7 to 12, even more preferably in the range of 8.9 to 10.9, for example approximately 9.9 parts mannose for every part galactose.
- the polysaccharides having a molecular weight in the range of 300,000 to 1 ,000,000 comprises in the range of 1 to 5, preferably in the range of 2 to 4, even more preferably in the range of 2.5 to 3.5, such as approximately 3.1 parts glucose for every part galactose. It is preferred that the polysaccharides of said composition having a molecular weight in the range of 300,000 to 1 ,000,000 Da comprise the monosacharides galactose, mannose, and glucose in the ratio 1 : 5 to 15:1 to 5, preferably the ratio is approximately 1:9.9:3.1.
- the composition comprises a mixture of polysaccharides, wherein the polysaccharides within said mixture having a molecular weight of at least 1 ,000,000 comprises in the range of 3 to 17, preferably in the range of 4 to 16, more preferably in the range of 5 to 15, even more preferably in the range of 6 to 14, yet more preferably in the range of 7 to 13, even more preferably in the range of 8 to 12, even more preferably in the range of 9.3 to 11.3, for example approximately 10.3 parts mannose for every part galactose.
- the polysaccharides having a molecular weight of at least 1 ,000,000 comprises in the range of 1 to 5, preferably in the range of 2 to 4, even more preferably in the range of 2.5 to 3.5, such as approximately 2.9 parts glucose for every part galactose. It is preferred that the polysaccharides of said composition having a molecular weight in the range of at least 1 ,000,000 Da comprise the monosacharides galactose, mannose, and glucose in the ratio 1 :4 to 1 :5 to 15:1 to 5, preferably the ratio is approximately 1:10.3:2.9.
- the polysaccharides according to the present invention have a molar ratio of galactose:mannose:glucose of 1 : 10 to 20 : 30 to 50, such as 1 : 12 to 18 : 35 to 45; for example 1 : 14 to 16 : 38 to 42, such as 1 : about 15 : about 40, for example 1 : 15 : 40.
- a composition the polypeptides comprise the monosaccharides galactose, mannose and glucose in the ratio (galactose : mannose : glucose) of 1 : 0 to 25 : 1 to 50, such as 1 : 10 to 20 : 30 to 50, such as 1 : 12 to 18 : 35 to 45; for example 1 : 14 to 16 : 38 to 42, such as 1 : about 15 : about 40, for example 1 : 15 : 40.
- the polysaccharides according to the present invention have a molar ratio of galactose:mannose:glucose of 1 : 0.5 to 5 : 6 to 12, such as 1 : 1 to 4 : 7 to 11 ; for example 1 : 1.5 to 3.5 : 7.5 to 10, such as 1 : 2.0 to 3.0 : 7.5 to 9.5, for example 1 : 2.2 to 2.8 : 8.0 to 9.0, such as 1 : about 2.5 : 8.0 to 9.0, for example 1 : 2.5 : 8.0 to 9.0, such as 1 : 2.5 : 8.6.
- composition of the present invention have a molar ratio of galactose:mannose:glucose of 1:12:40 and 1 :3:5.
- the sugar composition is obtainable from Agaricus blazei and comprises 10-20 parts mannose, 30-50 parts glucose and 0-2 parts galactose, such as e.g. 11-17 parts mannose, 35-45 parts glucose and 0-1 parts galactose. More preferably, the sugar composition is obtainable from Agaricus blazei and comprises about 15 parts mannose, about 40 parts glucose and about 1 part galactose, wherein "about” signifies within 20 % difference from the stated value, such as within 10 % difference from the stated value., such as within 5 % difference from the stated value.
- the sugar composition is obtainable from Ganoderma and comprises 0.5-5 parts mannose, 4-15 parts glucose and 0-2 parts galactose, such as e.g. 2-3 parts mannose, 7-9.5 parts glucose and 0.5-1.5 parts galactose. More preferably, the the sugar composition is obtainable from Ganoderma and comprises about 2.5 parts mannose, about 8.6 parts glucose and about 1 part galactose, wherein "about” signifies within 20 % difference from the stated value, such as within 10 % difference from the stated value, such as within 5 % difference from the stated value.
- Determination of the monosaccharide content of polysaccharides with a molecular weight within a given range may be determined by fractionating the composition according to size for example by ultrafiltration, microfiltration, ultracentrifugation or gelfiltration. For example this may be done as described in example 2.
- the mixture of polysaccharides comprises the monosaccharides galactose, mannose, and glucose in the ratio (0-1.5) : (0-0.5) to (15-35) : (0.5-1.5) to
- (45-55) such as e.g . any of the following: (0-1.5) : (0-0.5) to (15-35) : (0.5-1.5) to (45-55),
- the sugar composition of the composition of the present invention comprises 1-25 parts mannose, 5-45 parts glucose and 0-1.5 parts galactose; (by “part” is meant herein the relative molar ratio, i.e. for every 1-25 moles mannose, there are 5-45 moles of glucose and 0-1.5 moles of galactose), thus the sugar composition may comprise A), B) and C), as follows:
- a composition comprising one or more polypeptides and a mixture of polysaccharides, wherein: a) the majority of the polysaccharides of the composition have a molecular weight of at least 30,000 Da and wherein said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 1 :0 to 25:1 to 50, or b) the majority of the polysaccharides of the composition have a molecular weight of at least 100,000 Da and wherein said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 0 to 0.5:0.5 to 10:0.5 to 50, or c) the majority of the polysaccharides of the composition have a molecular weight of at least 1 ,000 Da and wherein said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 1 :0 to 25:1 to 50.
- the majority of the polysaccharides of the composition have a molecular weight of at least 10,000 Da, preferably at least 30,000 Da, and said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 1 :0 to 25:1 to 50, such as any of the following ratios:
- the majority of the polysaccharides of the composition have a molecular weight of at least 1,000 Da, such as at least
- said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 0 to 0.5:0.5 to 10:0.5 to 50, such as any of the following ratios:
- said ratio is about 0: 1 : 18 or about 0: 1 : 1.
- the majority of the polysaccharides of the composition have a molecular weight of at least 500 Da, such as at least 800 Da, such as at least 1 ,000 Da, for example at least 5,000 Da, for example at least 10,000 Da, such as at least 20,000 Da, for example at least 40,000 Da, such as at least 50,000 Da, for example at least 60,000 Da 75,000 Da, for example at least
- said mixture of polysaccharides comprises the monosaccharides galactose, mannose and glucose in the ratio 1 :0 to 25:1 to 50, such as any of the following ratios:
- said ratio is about 1:12:40 or about 1:3:5.
- composition according to the invention preferably comprises polypeptides.
- polypeptide as used herein covers both proteins, peptides and polypeptides. Said polypeptides may be in free form, they may be covalently linked to a polysaccharide or they may be non-covalently associated with a polysaccharide or a mixture of the aforementioned.
- the composition comprises sufficient polypeptide in order to allow for oral administration of the composition. If the composition comprises too little polypeptide, then no or little immune modulation is obtained in an individual after oral administration of the composition to said individual. It is therefore preferred that the composition of the invention comprises at least 10 ⁇ g/L, more preferably at least 20 ⁇ /L, even more preferably at least 25 ⁇ g/L, for example in the range of 10 to 1000 ⁇ g/L, such as in the range of 20 to 1000 ⁇ g/L, for example in the range of 25 to 1000 ⁇ g/L, such as in the range of 25 to 100 ⁇ g/L, for example in the range of 25 to 35 ⁇ g/L polypeptide, preferably soluble polypeptide.
- composition comprising the aforementioned concentration of polypeptide, comprises in the range of 0.1 to 2, more preferably in the range of 0.5 to 1.5, even more preferably around 1 mg/ml polysaccharide. If the composition comprises more or less polysaccharide it is preferred that the amount of polypeptide is proportionally reduced or enhanced.
- compositions of the invention are prepared by a method comprising the steps of
- Cultivating the fungus in a liquid growth medium in general involves dissolving nutrient compounds required for growth of said fungus in water, transferring the solution to a bioreactor and inoculating the bioreactor with cells or spores of the fungus, such as a fungal mycelium, or fractions thereof, to be cultivated. This is done under sterile conditions and with control of the environment in order to give the fungus a suitable chemical and physical environment. Cultivating fungi in liquid growth medium is also termed "liquid state" cultivation.
- the medium with the fungal biomass is preferably agitated to reduce the occurrence of gradients and to ensure oxygen availability to the submerged cells.
- oxygen may be supplied to the liquid medium and the level of dissolved oxygen may be controlled by known methods.
- the liquid growth medium is an aqueous solution, preferably sterile water, comprising nutrient compounds.
- the liquid medium supports fungal growth and preferably stimulates the production of extracellular compounds, such as immune modulating agents.
- the liquid growth medium may comprise one or more typical ingredients required for growth of microbial organisms such as malt extract, yeast extract, peptone, glucose, sucrose, sucrose, salts providing phosphate, magnesium and potassium, corn-steep liquor and vitamins such as thiamine. More preferably, the medium comprises sucrose, corns steep liquor, phosphate and magnesium for mycelium growth and production of polysaccharides.
- fungal mycelium such as Lentinus edodes mycelium from agar plates containing for example malt extract, yeast extract, peptone and glucose can be used.
- Fungi can initially be cultivated on agar plates comprising the above nutrient compounds supporting the growth of the fungus. The plates are inoculated with mycelium and incubated at least until a visible growth is evident on the plates.
- this usually can take from about 7 days to about 24 days or from about 10 to 30 days, typically 14 days or up to 20 days, at a temperature in the range of from 18 to 32 0 C, preferably in the area of from 22 to 3O 0 C, such as a temperature of about 23 0 C to 27 0 C, such as around 25°C.
- inoculation of the growth medium can be carried out by using mycelium from a fermentation broth in e.g. a shake flask medium comprising nutrient compounds supporting cell growth.
- Shake flasks for cultivating fungal mycelium can initially be inoculated with the mycelium which is cultivated on agar plates. The mycelium is taken from the plates and transferred aseptically to shake flasks containing sterile water comprising dissolved nutrient compounds and nutrient salts supporting the growth of the fungal mycelium.
- a typical growth medium contains sucrose, corn steep liquor, phosphate and a magnesium. The amount of inoculation material which gives the highest production of extracellular lentinan can be selected following initial experiments.
- the shake flasks can be incubated by shaking for 6 to 21 days, preferably from 7 to 18 days, more preferably from 8 to 14 days at a temperature in the range of from 18 to 32 0 C, preferably in the area of from 22 to 3O 0 C, such as a temperature of about 23 0 C, for example 24 0 C, such as 25 0 C 1 for example 26 0 C, such as 27 0 C, for example 28 0 C, such as 29 0 C, for example 3O 0 C.
- the shake flasks may also be incubated from 8-25 days, more preferably from 10-20 days, more preferably from 12-18 days.
- the temperature may also be from 18 to 37°C, preferably from 23 to 32 0 C such as about 25°C.
- the content of the shake flasks can be used for inoculating a bioreactor.
- the reactor comprises a sterile solution of nutrient compounds and nutrient salts in water for mono-culture cultivation of basidiomycete fungal mycelium, or fractions thereof, such as Lentinus fungal mycelium, such as Lentinus edodes.
- the bioreactor fermentation period is typically in the range of from 50 hours to 300 hours, preferably in the range of from 80 hours to 270 hours, and the temperature is kept constant in the range of 18 to 32 0 C, preferably in the area of from 22 to 31 0 C, such as a temperature of about 23 0 C, for example 24 0 C, such as 25 0 C, for example
- the temperature may also be from 18 to 37 0 C, preferably from 23 to 32°C such as about 25°C.
- the reactor is fitted with an inlet for supplying air to the fermentation broth, and the fermentation broth is preferably kept under continuous agitation either as a result of the addition of air, or by means of a mixer device suitable for providing a good mixing of the content of the reactor.
- the pH of the growth medium is adjusted to from about 3 to about 7, such as a pH of from about 4.5 to about 6.5, for example a pH of about 6, before the growth medium is inoculated with fungal mycelium, or fractions thereof, such as L. edodes mycelium.
- pH may be dropped naturally during the course of the fermentation, or controlled at a particular value in the range pH 3 to 7, using addition of suitable pH-control agents, such as acid and base.
- the temperature of the growth medium is preferably in the range of from 18 to 32 0 C, preferably in the area of from 22 to 31 0 C, such as a temperature of about 23 0 C, for example 24 0 C, such as 25 0 C, for example 26 0 C, such as 27 0 C, for example 28 0 C, such as 29 0 C, for example 3O 0 C.
- the temperature may also be from 18 to 37 0 C, preferably from 23 to 32°C such as about 25 0 C.
- Samples can be obtained from the bioreactor and analysed for biomass, metabolic products and nutrient compounds, the determinations of which can assist the operator of the bioreactor in the running of the fermentation process. Typical analyses routinely carried out are determination of biomass, residual sugar concentration and extracellular polysaccharide concentration. A person skilled in the art knows the methods for analysis which can be employed in this respect.
- the method for preparing the compositions according to the invention involves a step of purifying the extracellular fraction of the liquid growth medium from the fungal mycelium.
- the extracellular fraction of the liquid fermentation medium is also termed the supernatant and this fraction can be separated from the fungal mycelium by e.g.
- the term "essentially without any fungal mycelium present therein” shall denote that the concentration of fungal mycelium, including fractions thereof, has been reduced at least by a factor of 10 3 , such as reduced by a factor of at least 10 4 , for example a factor of at least 10 5 , such as reduced by a factor of at least 10 6 .
- the purification comprises at least one size fractionation step.
- this size fractionation step is performed on the extracellular fraction.
- This size fractionation step may ensure that every polysaccharide of the composition has a molecular weight of at least a given value (see also herein above).
- the size fractionation step may be any size fraction known to the skilled person, for example ultracentrifugation, ultrafiltration, microfiltration or gelfiltration.
- the composition is purified from a liquid growth medium by a method involving one or more purification steps selected from the group consisting of ultracentrifugation, ultrafiltration, microfiltration and gelfiltration.
- the purification step(s) are selected from the group consisting of ultrafiltration, microfiltration and ultracentrifucation, even more preferably from the group consisting of ultrafiltration and microfiltration.
- Ultrafiltration is a membrane process where the membrane fractionates components of a liquid according to size.
- the membrane configuration is normally cross-flow wherein the liquid containing the relevant components are flowing across the membrane. Some of the liquid, containing components smaller than the nominal pore size of the membrane will permeate through the membrane. Molecules larger than the nominal pore size will be retained.
- the desired product may be in the retentate or the filtrate. If the ultrafiltration is performed in order to prepare a composition, wherein every polysaccharide within said composition has a molecular weight above a given value, the desired product is in the retentate. If a serial fractionation is made, the product may be in the retentate or filtrate.
- Microfiltration is a membrane separation process similar to UF but with even larger membrane pore size allowing larger particles to pass through.
- Gel filtration is a chromatographic technique in which particles are separated according to size.
- the filtration medium will typically be small gel beads which will take up the molecules that can pass through the bead pores. Larger molecules will pass through the column without being taken up by the beads.
- Gel-filtration, ultrafiltration or microfiltration may for example be performed as desribed in R Hatti-Kaul and B Mattiasson (2001), Downstream Processing in Biotechnology, in Basic Biotechnology, eds C Ratledge and B Kristiansen, Cambridge University Press) pp 189.
- compositions according to the invention are described in e.g. examples 1 , 7 and 8.
- the method therefore does not involve an alcohol precipitation step, more preferably the method does not involve a precipitation step.
- compositions of the invention in a method for stimulating the immune system of an individual in need of such stimulation.
- the composition may be administered e.g. orally or subcutaneously to the individual in a pharmaceutically effective amount capable of stimulating the immune system of the individual.
- the stimulation of the immune system can be demonstrated by e.g. increased antibody production, by activation of helper T-cells, or by increased production of interleukins such as lnterleukin 1 and lnterleukin 2.
- compositions of the invention in the manufacture of a medicament for treating an immune compromised condition in an individual in need of such treatment.
- An immune compromised condition in an individual may be demonstrated e.g.
- the immune compromised condition may be any of those disclosed below.
- the treatment may be prophylactic, ameliorating or curative.
- Insufficient amount and “decreased production” as used herein above shall denote such amounts and productions which a medical expert considers as being below a predetermined level or value normally associated with a healthy individual.
- the amount and/or production will generally depend on factors such as age, general physical condition, and the like. For this reason a predetermined level or value shall be determined on an individual basis by a medical expert.
- One indication of an immune compromised condition in an individual is a gradually decreasing number of antibodies, a gradually decreasing number of CD4 (positive) cells, or a gradually decreasing number of T-helper cells per unit (blood) sample volume measured over time, such as days, weeks, months or years.
- the present invention relates to pharmaceutical compositions comprising the composition according to the invention and pharmaceutically acceptable carrier(s).
- the pharmaceutical compositions may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pa.
- the compositions may appear in conventional forms, for example capsules, tablets, lozenges, powders, syrups, solutions or suspensions.
- the invention relates to a method of treatment of an individual diagnosed with an immune compromised condition, said method comprising the steps of administering to said individual the composition according to the invention or the pharmaceutical composition according to the invention in an amount effective in treating said immune compromised condition.
- the administered amount may in be an amount effective in prophylactically treating said immune compromised condition.
- a method of treatment of an individual diagnosed with or at risk of contracting acquired immunodeficiency syndrome comprising the steps of administering to said individual the composition according to the invention or the pharmaceutical composition according to the invention in an amount effective in treating or prophylactically treating said syndrome.
- the immune compromised condition may be selected from the group consisting of an infectious disease, a parasitic disease, haemophilus meningitis, pneumococcal meningitis, streptococcal meningitis, staphylococcal meningitis, meningitis due to other organisms, encephalitis, viral pneumonia, pneumococcal pneumonia, other bacterial pneumonia, pneumonia due to other specified organisms except bacteria, bronchopneumonia, organism unspecific pneumonia, influenza, unspecified diarrhea, hepatitis unspecified, acute and subacute necrosis of the liver, chronic hepatitis, and abscess of liver.
- the immune compromised condition may be an infectious or parasitic disease caused by, or selected from, cholera, salmonella, shigellosis, Escherichia coli, intestinal infection due to other specified bacteria, Clostridium difficile, viral gastroenteritis, infectious colitis, enteritis and gastroenteritis, infectious diarrhea, tuberculosis, listeriosis, pasteurellosis, mycobacterium, diphtheria, pertussis, meningococcus, streptococcus septicaemia, staphylococcus septicaemia, pneumococcal septicaemia, septicaemia due to anaerobes, septicaemia due to other gram-negative organisms, actinomycotic infection, gas gangrene, toxic shock syndrome, necrotizing faciitis, Friedlander's bacillus, haemophilus influenzae, pseudomonas, AIDS/HIV infections, acute poliomyelitis, Creutzfeldt-Jacob disease, suba
- the individual may be a mammal, such as a human being.
- compositions of the invention may be administered using any suitable administration form; usually however, administration will be oral or parenteral. Oral administration in the form of a syrup comprising the composition and/or a capsule containing a syrup comprising the composition or in a powder form of the composition is preferred.
- the dosage requirements will vary with the particular composition employed, the route of administration and the particular individual being treated. Ideally, an individual to be treated by the present method will receive a pharmaceutically effective amount of the compound in the maximum tolerated dose.
- the daily oral dosage regimen may be about 0.001 to about 100 mg/kg, preferably in the range of 0.01 to 50 mg/kg, more preferably in the range of 0.1 to 10, even more preferably in the range of 1 to 2 mg/kg of total body weight.
- the optimal quantity and spacing of individual dosages of the composition will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques.
- the optimal course of treatment i.e., the number of doses of the composition given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
- compositions and the pharmaceutical compositions according to the invention may also form part of a kit comprising said compositions and a dosage regime instruction with guidelines for dose and time administration.
- the composition of the present invention is used in the manufacture of a functional food, thus in one embodiment of the present invention, any of the compositions described herein may be comprised in a functional food or nutrition supplement, preferably suitable for human beings.
- Said functional food is preferably a survival enhancing, longevity enhancing, health enhancing and/or a modulator of a microbial population. More preferably, said functional food is health enhancing and/or a modulator of a microbial population. It is preferred that the functional food is suitable for at least weekly oral intake, such as for daily oral intake.
- said functional food product may be suitable for use in parenteral or enteral nutrition, preferably in combination with formulations comprising other nutrients known to one skilled in the art.
- Products according to the invention may be used for promoting health of human beings, for example for maintaining, strengthening or promoting bone or cardiovascular health.
- the functional food can be used for the prevention or reduction of osteoporosis.
- regular consumption of said functional food such as for example once a day, twice a day, or three times a day, leads to a reduction of the risk of diseases such as colds, coughs and reduces tiredness and fatigue.
- the functional food is preferably ingested by a human as an ingredient of his or her daily diet.
- a liquid vehicle such as water, milk, vegetable oil, juice and the like, or with an ingestible solid or semi-solid foodstuff.
- the present invention thus relates to a method of producing a functional food composition, comprising mixing any of the compositions described herein (for example obtained from Lentinus fungus) with a foodstuff.
- said functional food product may be selected from the group of meal replacers, dietary supplements, ice-cream, sauces, dressing, spreads, bars, sweets, snacks, cereals and beverages.
- said functional food is dietary supplement, preferably suitable for ingestion in pill, capsule, tablet or liquid form.
- products according to the invention are prepared whereby any of the compocsitions described herein (such as from Lentinus) is added to the food product such that the level of the composition is between 5 to 5000 mg per 100 g product.
- the functional food is a dairy product.
- said functional food may for example be selected from any of the following: cultured dairy products, yogurts, cottage cheese, cream cheese, dairy dips, sour cream, milkshakes, Butter, Margarine, Low-fat spreads, Cheese, Cottage cheese, Cheese spread, Cheese "strings” for children.
- said dairy product is a cheese-based product, such as selected from low-fat cheese, hard cheese, soft cheese, cottage cheese, cheese spread, cheese "strings” for children or cheese slices suitable for sandwiches.
- said dairy product is a yoghurt-based product, such as selected from a set yoghurt, a runny or pourable yoghurt, a yoghurt-based carbonated drink, a drinking or drinkable yoghurt, a low-fat yoghurt.
- Said yoghurt-based product may for example be fermented with Lactobacillus bulgaricus and/or Streptococcus thermophilus.
- said dairy product is a cultured dairy product, such as a cultured fluid (for example drinkable yogurt/yogurt smoothies, kefir, probiotic shots); a non-drinkable yogurt (for example in a cup or tubes); and/or another non-pourable cultured dairy product (for example cottage cheese, cream cheese, dairy dips or sour cream).
- a cultured fluid for example drinkable yogurt/yogurt smoothies, kefir, probiotic shots
- a non-drinkable yogurt for example in a cup or tubes
- another non-pourable cultured dairy product for example cottage cheese, cream cheese, dairy dips or sour cream.
- said dairy product is another type of dairy product, such as selected from the group consisting of: refrigerated dips and sour cream, ice cream, cream, low-fat cream-replacement, fermented milk such as kefir, fermented beverages, such as drinkable yoghurt and kefir.
- the functional food according to the present invention is a health drink.
- Said health drink is in one embodiment fruit juice-based, which may be concentrated as a "squash", to be diluted to taste.
- Said fruit juice or squash preferably comprises concentrated fruit juice.
- Preferred fruit juices include, but are not restricted to, citrus fruit juices such as orange, grapefruit, lemon or lime, or combinations thereof.
- said fruit juice or squash comprises (preferably concentrated) berry juice(s), such as from raspberries, strawberries, blackberries, loganberries, cranberries, redcurrants, blackcurrants, blueberries, or combinations thereof, and/or combinations with citrus fruit juices.
- said fruit juice or squash comprises juice(s) from one or more of Pineapple, Passion Fruit, Mango, apple, pear, apricot, Pomegranate, guava, tomato and/or combinations with any other types of fruit juices.
- Preferred juice bases are selected from the following group:
- Said health drink may also be water-based, such as a mineral water-based product, such as flavoured mineral water-based products.
- Said flavouring is preferably from fruit juices and/or other natural products.
- said health drink is an energy shot comprising sugars and other energy-providing products, such as comprised in an 25 or 30 cl bottle.
- said health drink is an alcoholic beverage, such as a dairy-based alcoholic beverage.
- said health drink is a meal replacement drinks. It is envisaged that the health drink of the present invention may also be manufactured as a concentrate or premix, ready for making up to the drink at a later stage, preferably by the consumer.
- the functional food is a solid functional food, such as selected from the group consisting of: Biscuits/crackers, breakfast cereal, soup, muesli, Chewing gum, Sweets (such as boiled sweets), fresh bakery products (fresh bread, cakes, muffins, waffles etc.), dry bakery products (crispbread, biscuits, crackers etc.), cereal products (breakfast cereals, fibre and sterol enriched flours, mueslis, cereal based and muesli bars, such bars possibly containing chocolate, pasta products, snacks etc.), bran products (granulated and/or toasted bran products, flavoured and/or sterol coated bran products and bran-bran mixes etc.).
- Biscuits/crackers such as selected from the group consisting of: Biscuits/crackers, breakfast cereal, soup, muesli, Chewing gum, Sweets (such as boiled sweets), fresh bakery products (fresh bread, cakes, muffins, waffles etc.), dry bakery products (crispbread
- said solid functional food is a ready mix (preferably in powder form), either for baking (e.g. breads, cakes, muffins, waffles, pizzas, pancakes) or for cooking (e.g. soups, sauces, desserts, puddings) to be used in preparing or manufacturing of foods
- baking e.g. breads, cakes, muffins, waffles, pizzas, pancakes
- cooking e.g. soups, sauces, desserts, puddings
- said solid functional food is a meat product (sausages, meat-balls, cold cuts etc.)
- said solid functional food is a bread or morning product/bakery snack.
- said bread may be white, brown or wholemeal bread.
- said bread may be selected from the following bread types: malted wheats, milk breads, bran-enriched and mixed grain breads.
- the bread may be any shape, such as e.g. cob, coburg, cottage, cholla, bloomer, barrel, batch, sandwich, tin, Vienna or farmhouse.
- said bread is selected from any of the following bread types:
- Softgrain bread made from white flour with additional grains of softened rye and wheat to increase the fibre content (preferably by 30%) compared with conventional white bread)
- said bread is selected from any of the following bread types:
- Soda Bread or brown soda bread (made using wholemeal flour) rye breads baguette or French stick croissants bagel
- said bread is a flat bread, such as selected from any of the following bread types: Chapattis, Paratas and Roti, Mexican tortilla, flat "wrap” or flour tortilla, pancakes.
- the functional food is a morning snack or bakery product.
- Said bakery product may be either sweet or savoury, for example savoury.
- Preferred bakery products include, but are not restricted to: rolls and baps, toasting products such as muffins, crumpets and pikelets, scones, teacakes, buns and other fruited products, hot plate products such as pancakes and griddle scones, waffles and potato cakes, hot cross buns, croissants, brioches, pain-au-chocolat, bagels, American sweet muffins and other semi-sweet bread products.
- toasting products such as muffins, crumpets and pikelets
- scones teacakes
- hot plate products such as pancakes and griddle scones, waffles and potato cakes
- hot cross buns croissants, brioches, pain-au-chocolat, bagels, American sweet muffins and other semi-sweet bread products.
- the functional food is a vegetable oil-based product (spreads, salad oils, mayonnaise etc.)
- the functional food is a frozen confectionary product.
- frozen confectionery product includes milk containing frozen confections such as ice- cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen custard, water-ices, granitas and frozen fruit purees.
- the level of solids in the frozen confection is more than 3 wt %, more preferred from 10 to 70 wt %, for example 40 to 70 wt %.
- Ice-cream will typically comprise 2 to 20 wt % of fat, 0 to 20 wt % of sweeteners, 2 to 20 wt % of non-fat milk components and optional components such as emulsifiers, stabilisers, preservatives, flavouring ingredients, vitamins, minerals, etc, the balance being water.
- ice-cream will be aerated e.g. to an overrun of 20 to 400 %, more general 40 to 200 % and frozen to a temperature of from -2 to -200 degrees. C, more general -10 to -30 degrees C. Ice-cream normally comprises calcium at a level of about 0.1 wt %.
- composition according to the present invention may be encapsulated or combined with emulsifiers, detergents or other agents to ensure solubilisation and stabilisation of the substance in the product.
- the functional food is a meal replacer.
- Meal replacer drinks are typically based on a liquid base which may for example be thickened by means of gums or fibers and whereto a cocktail of minerals and vitamins are added.
- the drink can be flavoured to the desired taste e.g. fruit or choco flavour.
- a typical serving size may be 330 ml or 330 g.
- the composition according to the present invention may be encapsulated or combined with emulsifiers, detergents or other agents to ensure solubilisation and stabilisation of the substance in the beverage.
- Meal replacer snacks or bars often comprise a matrix of edible material wherein the composition according to the present invention can be incorporated.
- the matrix may be fat based (e.g. couverture or chocolate) or may be based on bakery products (bread, dough, cookies etc) or may be based on agglomerated particles (rice, grain, nuts, raisins, fruit particles).
- a typical size for a snack or meal replacement bar could be 20-200 g, generally from 40 to 100 g.
- Further ingredients may be added to the product e.g. flavouring materials, vitamins, minerals etc.
- the functional food comprises a composition according to the present invention in combination with another survival enhancing agent, longevity enhancing agent, health enhancing agent and/or a modulator of a microbial population.
- one preferred embodiment of said functional food is a food comprising one or more of the compositions according to the present invention and a probiotic, such as in a probiotic "shot".
- Another preferred embodiment of the functional food is a food comprising the compounds according to the present invention and a prebiotic, such as in a prebiotic "shot”.
- Another preferred embodiment of the functional food is a food comprising the compositions according to the present invention and a symbiotic, such as in a symbiotic "shot”.
- preferred bacteria for use in the above- mentioned shots are any of the following: Lactobacillus sp., such as L. acidophilus, L. casei, L. fermentum, L. johnsonii, L.
- preferred bacteria for use in the above-mentioned shots are any of the following: Bifidobacterium sp., such as B. bifidium, B. breve, B. lactis, and/or B. longum.
- preferred bacteria for use in the above-mentioned shots are any of the following: Enterococcus faecalis. Escherichia coli, Saccharomyces boulardii, Saccharomyces cerevisiae and/or Streptococcus thermophilus.
- composition according to the present invention may be also combined with other ingredients in a dietary supplement, such as e.g. botanical supplements and/or in a vitamin E capsules, or in a selenium pill. Further preferred combination in said dietary supplements may be with e.g. one or more of the following: antioxidant(s), vitamin C, vitamin E, beta-carotene
- the functional food of the invention can further encompass other healthy components such as for example vitamins A, B, C, D, E, minerals such as calcium, - potassium, magnesium, iron, copper, zinc, selenium and anti-oxidants such as tocopherols, polyphenols.
- the functional food may comprise a composition according to the invention (such as lentinan) together with vitamin C, the combination capable of causing a reduction in colds and flu in the individual ingesting said functional food.
- compositions of the invention may comprise further ingredients which are believed to reduce or prevent osteoporosis.
- ingredients which are believed to reduce or prevent osteoporosis. Examples of such ingredients are calcium, vitamin D, magnesium etc.
- Beverage comprising any of the compositions described herein in an amount of 0.1- 5%, preferably 0.5-1%.
- Fresh bakery product comprising any of the compositions described herein in an amount of 0.9-16%, preferably 2.4-10%, and more preferably 3-5%.
- Dry bakery product comprising any of the compositions described herein in an amount of 1.0-20%, preferably 3.2-15% and more preferably 4.4-10%
- Cereal product comprising any of the compositions described herein in an amount of 0.8-20%, preferably 1.6-16%, more preferably 2-10%
- Bran product comprising any of the compositions described herein in an amount of 4%-25%, preferably 6-20% Dairy or non-dairy product (e.g. fermentated cereal product) comprising any of the compositions described herein in an amount of 0.1-20%, preferably 0.8-8%
- Vegetable oil based product comprising any of the compositions described herein in an amount of 0.6-16%, preferably 2.6-10%, more preferably 2.6-5%
- Meat product comprising any of the compositions described herein in an amount of 0.1-16%, preferably 0.2-5%.
- Dairy product comprising: any of the compositions described herein in an amount of 0.1-16%, preferably 0.2-5%.
- the present invention is concerned with use of any of the compositions described herein in the manufacture of a functional food, such as any of the functional foods described herein.
- Lentinus edodes was cultivated in liquid culture in medium comprising 15 g/l glucose, 3g/l malt extract, 3 g/l yeast extract and 5 g/l peptone in shake flasks at 25°C. After cultivation the biomass was separated from the rest of the fermentation broth by filtration. The supernatant was subjected to ultrafiltration using a membrane with a nominal pore size of 50,000 Da. The retentate (herein designated the "MediMush product”) was used for analysis of monosaccharide content. For comparison, commercially available Lentinan for injection (Eureka Bio- Chemicals Pty, Little Collins Street. Melbourne 3000, Australia) was used in a reference experiment performed in parallel (herein after this product is designated "Eureka").
- Samples were hydrolysed to their constituent monosaccharides in 1 N HCI at 100 0 C.
- the hydrolysates were analysed by HPLC using a Dionex MA-1 column with 60OmM NaOH as the mobile phase; detection was by pulsed amperometry.
- the major monosaccharides of the MediMush product was mannose and glucose and some galactose.
- Table A displays the relative monosaccharide content of the MediMush product and Eureka.
- Soluble protein in the samples was measured by a microscale version of the Coomassie dye-binding assay (Mousdale, D. M, Campbell, M.S., Coggins, J. R. "Purification and characterisation of bifunctional dehydroquinase-shikimate:NADP dehydrogenase from pea seedlings". Phytochemistry 367, 217-222 (1987). The amounts of soluble protein in the two products are shown below:
- P388 cells are mouse macrophage like cells, which secrete large amounts of interleukin-1 (IL-1) when stimulated (detailed information on the cells is available from the ECACC).
- the amount of IL-1 secreted can be quantified using an ELISA (Enzyme-Linked ImmunoabSorbant Assay) based method and used as a measure of how stimulated the cells are. It should be noted that no absolute value exist to calibrate such an assay and it is therefore preferred that a reference sample is analysed in parallel and the IL1 production is evaluated as compared to the IL1 production induced by the reference sample.
- the P388 cells are seeded in a 12 well culture plate and allowed to grow overnight. The various stimulants are added at differing concentrations and incubated at 37 0 C for 24 hr.
- ELISA Enzyme-Linked ImmunoabSorbant Assay
- IL-1 antigen
- the IL-1 is detected using two antibodies against the two different forms of IL-1 , which are raised in a goat (primary antibodies).
- the next step uses another antibody, which detects the goat antibody (secondary antibody).
- the antibody is conjugated to horse- radish peroxidase, which gives a colour reaction when substrate is added.
- the amount of colour measured by a spectrophotometer (ELISA reader) correlates with the amount of IL-1 present thus quantifying how stimulated the tissue culture cells are.
- the MediMush product was markedly immunostimulatory.
- the Eureka product showed some immunostimulation but was significantly weaker than the MediMush product.
- the MediMush product induced production of 58 times more IL1 ⁇ and 20 times more IL1- ⁇ than Eureka.
- the immune stimulating activity of the MediMush product prepared as described in example 1 was compared to the immune stimulating activity of a polysaccharide composition, which had not been subjected to size fractionation.
- This product was prepared by cultivating Lentinus edodes in liquid culture as described in example 1. To the supernatant thus obtained around 2 volumes of absolute ethanol was added to precipitate the product. The precipitate was removed, washed with absolute ethanol and re-suspended in distilled water.
- the immune stimulation assay was performed as described in example 4.
- the results using the MediMush product is given in table 5 and the results using the precipitated product are given in table 6.
- the following method may be used: 12 weeks old Sprague Dawley rats receives 1 mg of the composition according to the invention in 0.5 ml 0.09 saline (i.p.) 2 days before the immunisation. Control animals receives 1 mg casein. The animals are immunised with BSA (0.5 mg) in 0.25 "Freunds Complete Adjuvant" and blood samples are obtained after 11 days for measurement of the antibody response. The specific anti-BSA antibody concentration is determined against an absolute standard of antibody BSA by means of "sandwich" ELISA.
- Biomass Remove the biomass from the broth using a nylon cloth with pore size 45 as a filter medium. Wash the biomass thoroughly with water and dry in a microwave oven set at defrost until dry (normal sample size will require about 15 mins). Store in a desiccator until cool and weigh.
- Fermentation liquor The concentration of immunostimulating agent in the fermentation liquor is determined by ppt with abs ethanol. Sterile, distilled water is added if necessary to adjust the concentration to the desired level. The resulting liquid is autoclave and stored.
- Medical grade Pass the biomass-free fermentation liquor through a UF filter having a mwt cut-off such as for example 300 kD. When 70-80% of the liquid has been removed add water to the retentate to wash the solution. Repeat until the solution has lost much (most of) its colour and appears clean.
- Example 7b Agaricus blazei was cultivated as described in Example 7a, in liquid culture. After cultivation the biomass was separated from the rest of the fermentation broth by filtration. The supernatant was subjected to centrifugal filtration using filters with different mwt cut offs. The first product (denoted MediMush product II) was obtained by removing all components below 10OkD with the remaining liquid containing the product MediMush II. The second product (denoted MediMush product III) was obtained by removing all components from the supernatant having a mwt below 1kD with the remaining liquid containing "Medimush product III ".
- Samples were hydrolysed to their constituent monosaccharides in 1N HCI at 100 0 C.
- the hydrolysates were analysed by HPLC using a Dionex MA-1 column with 60OmM NaOH as the mobile phase; detection was by pulsed amperometry.
- the major monosaccharides of the MediMush products Il and III were mannose and glucose and some galactose.
- Table B displays the relative monosaccharide content of the MediMush products Il and III .
- Ganoderma lucidum was cultivated in a similar way as the Agaricus fungus as described in Example 7a, in liquid culture. After cultivation the biomass was separated from the rest of the fermentation broth by filtration. The supernatant was subjected to centrifugal filtration, as illustrated in Example 7a.
- the first product (denoted MediMush product IV ) was obtained by removing all components below 10OkD with the remaining liquid containing the product MediMush IV.
- the second product (denoted MediMush product V) was obtained by removing all components from the supernatant having a mwt below 1 kD with the remaining liquid containing "Medimush product V ".
- mice Twenty-four, 5 week-old, male mice were used in these studies. They were purchased from the Division of Laboratory Animal Medicine, Louisiana State
- Medimush Product treatment Mice were divided into four groups. Group 1 received 2 mg/kg lentinian in 0.15 M NaCI, intraperitoneal ⁇ (i.p.), group 2 received an equal volume of saline i.p., group 3 received 10 mg/kg Medimush Product in water by gastic gavage (oral) and group 4 received an equal volume of water orally. All mice received treatment once daily for 5 days. Twenty four hours after the last treatment the mice were bled and euthanized for cell isolation. Isolation and stimulation of peritoneal exudates cells (PEC): PEC were collected by peritoneal lavage as previously described (1).
- PEC peritoneal exudates cells
- Cells were concentrated to 1 x 10 6 / mL in RPMI 1640 supplemented with 2 mM L-glutamine, 100 units/mL penicillin and 100 ⁇ g/mL streptomycin (medium) and distributed to 24 well tissue culture plates at 1 mL/well. Plates were centrifuged at 1200 x g for 10 min and placed at 37 0 C, 5%CO 2 for 2 hours. Medium was discarded and the wells washed once with warm medium and replaced with 1.5 ml. warm medium supplemented with 10% fetal bovine serum (Hyclone, Inc. Logan, UT) (complete medium). Half the wells from each group were treated with E.
- LPS coli lipopolysaccharide
- the phenotype of the cells was determined by flow cytometry using antibodies to CD3 and CD14 (eBioscience, San Diego, CA) labeled with phycoerythrin and anti-mouse IgG labeled with fluorescein (Jackson ImmunoResearch, Avondale, PA).
- Isolation and stimulation of splenocytes Spleens were harvested from each mouse. A portion was snap frozen for future mRNA analysis.
- the remaining spleens were pooled by group and crushed through a 70 ⁇ m nylon screen (Becton Dickenson Labware, Franklin Lakes, NJ). Splenocytes were washed once and the pellet resuspended in buffered ammonium chloride for 5 min on ice. Cells were washed twice and resuspended at 4 x 10 7 VmL in complete medium distributed to 24 well tissue culture plates at 1.5 mL/well. Representative wells were stimulated with E. coli LPS at 10 ng/ml or Concanavilin A (ConA; Sigma Chemical Co.) at 5 ⁇ g/mL and the cells were placed at 37 0 C, 5%CO 2 for 12 or 24 hours. ELISA for cytokines.
- Cytokine ELISA for TNF ⁇ , IL-1 ⁇ , IL-6 and IL-12 were conducted on serum and culture supernatants exactly as described by the manufacturer (eBioscience). Undiluted supernatants were tested in triplicate. Serum was diluted 1 : 10 for testing.
- Medimush Product had no statistically significant effect on their growth as measured by weight gain (Table 1). However, i.p. Medimush Product had an effect on the number and phenotype of the cells isolated from the peritoneum lavage. Orally exposed mice and those that received saline i.p were relatively similar; however, there was a increase in the total number of cells isolated from the peritoneum of i.p. Medimush Product treated mice (data not shown). The increased number of cells was due mainly to an increase in neutrophils in the population (Table 2). The relative contribution to the observed results by the PMN compared to macrophage cannot be estimated at this time, but might effect the difference observed differences in the i.p. groups.
- IL-1 ⁇ production by PEC (18-fold and 6-fold, respectively; Table 4).
- IL-1 ⁇ in response to in vitro LPS was also increased more than 3-fold in ip treated mice
- IL-1 ⁇ production by PEC from mice exposed to oral Medimush Product and stimulated in vitro LPS was decreased (2-fold).
- Splenocytes from treated and untreated mice produce small amounts of IL-1 ⁇ in the first 12 hours of culture.
- splenocytes from the mice were stimulated to produce IL-1 ⁇ by treatment with either LPS or ConA (a T cell mitogen).
- Oral Medimush Product exposure generally decreased pro- inflammatory cytokine production by PEC and increased pro-inflammatory production by splenocytes suggesting the systemic response to Medimush Product (oral) may be different from the local responses measured in previous studies (nasal, i.p., i.v.).
- intraperitoneal control 6 14 17 46 18 intraperitoneal Medimush 4 3 84 6
- Medimush Product P c intraperitoneal none 1 + 1 5 + 1** 0.0084 intraperitoneal LPS 2 + 0 49 + 9** 0.0015 intraperitoneal Con A 4 + 2 13 + 3 0.0717 oral none 3+ 1 3 + 0 0.7811 oral LPS 3 + 0 11 + 1** 0.0213 oral ConA 3 + 1 11 + 2 0.0969 a.
- Medimush Product P c intraperitoneal none 567 + 25 320 + 33** 0.0194 intraperitoneal LPS 265 + 15 286 + 54 0.5657 oral non 288 + 30 247 + 30** 0.0027 oral LPS 258 + 31 209 + 17 0.8763 a.
- Medimush Product P c intraperitoneal none 132 + 2 344 + 30** 0.0098 intraperitoneal LPS 299+ 10 367 + 31 _ 0.0853 intraperitoneal Con A 393 + 19 233 + 24** 0.0029 oral none 114 + 2 199 + 7** 0.0014 oral LPS 367 + 31 329+ 11** 0.0124 oral ConA 233 + 24 248 + 25** 0.0284 a.
- Medimush Product P c intraperitoneal none 101 + 2 272 + 5** 0.0009 intraperitoneal LPS 624 + 15 932 + 17 0.0011 oral none 764 + 10 852 + 43 0.0833 oral LPS 835 + 29 760 + 77 0..3680 a.
- Limit of detection 8 pg/ml b. 0.15 M saline was used as a control for intraperitoneal injections and distilled water was used as a control for oral exposure.
- Medimush Product P c intraperitoneal none 105 + 6 638 + 18** 0.0004 intraperitoneal LPS 218+ 16 524 + 33** 0.0042 intraperitoneal Con A 567 + 7 835 + 39** 0.0029 oral none 117 + 5 190 + 3** 0.0007 oral LPS 174 + 5 266+ 3** 0.0065 oral ConA 326 + 6 510 + 11** 0.0039 a.
- Medimush Product P c intraperitoneal none 1 + 1 11 + 5 0.1017 intraperitoneal LPS 13 + 9 2 + 1 0.2611 intraperitoneal Con A 96 + 11 86 + 8 0.4155 oral none 2 + 2 0 + 0 0.3855 oral LPS 4 + 4 1 + 1 0.4405 oral ConA 71 + 11 80 + 7 0.2293 a.
- Example 10 Bar 75 g of dark chocolate are melted at 70 degrees C and subsequently mixed with 600 mg of Medimush product. The mixture is poured into a bar shaped mold and cooled overnight.
- vanilla flavoured ice-cream 100 ml of vanilla flavoured ice-cream are mixed with 100 ml of cooled milk, 10 ml of strawberry syrup and 1 ml extracellular liquid from mushroom cultivation. The mixture is fed through a blender and immediately served.
- Method of preparation dissolve hyfoama and gelatin in water add 150 g of sugar and beat to foam, heat remaining sugar to 130 degrees C and add slowly to foam. Add fat, glucose syrup, milkpowder and 1 g extracellular liquid from mushroom cultivation. Allow to cool and divide in bars of 50 g.
- Example 13 Fruit Drink
Abstract
Description
Claims
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/892,393 US7514085B2 (en) | 2004-07-16 | 2004-07-16 | Immune modulating compounds from fungi |
US69048205P | 2005-06-15 | 2005-06-15 | |
US69047705P | 2005-06-15 | 2005-06-15 | |
US69049605P | 2005-06-15 | 2005-06-15 | |
DKPA200500881 | 2005-06-15 | ||
DKPA200500882 | 2005-06-15 | ||
DKPA200500880 | 2005-06-15 | ||
PCT/DK2005/000498 WO2006007848A2 (en) | 2004-07-16 | 2005-07-15 | Immune modulating compounds from fungi |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1774012A2 true EP1774012A2 (en) | 2007-04-18 |
Family
ID=35414957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05758000A Withdrawn EP1774012A2 (en) | 2004-07-16 | 2005-07-15 | Immune modulating compounds from fungi |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1774012A2 (en) |
JP (3) | JP2008525311A (en) |
KR (1) | KR20070057803A (en) |
AU (1) | AU2005263329A1 (en) |
CA (1) | CA2574060C (en) |
IL (1) | IL180713A0 (en) |
TW (1) | TW200607863A (en) |
WO (1) | WO2006007848A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO20014256D0 (en) | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Preparation of immunostimulatory compound |
WO2006133708A1 (en) * | 2005-06-15 | 2006-12-21 | Medimush A/S | Bioactive agents produced by submerged cultivation of a basidiomycete cell |
EP1896600A2 (en) * | 2005-06-15 | 2008-03-12 | Medimush A/S | Anti-cancer combination treatment and kit-of-part |
KR100825119B1 (en) * | 2006-12-29 | 2008-04-25 | 영남대학교 산학협력단 | Pharmaceutical composition for preventing and treating liver disease |
CA2799569A1 (en) * | 2009-05-15 | 2010-11-18 | Her Majesty The Queen In Right Of The Province Of Nova Scotia, As Represented By The Nova Scotia Agricultural College (Nsac) On Behalf Of The Minister Of The Agriculture | Stable functional beverage compositions and processes for making same |
KR101695488B1 (en) * | 2013-12-06 | 2017-01-23 | 한명순 | Composition for preventing and improving of diarrohea, and oral syringe package using the same |
WO2015083982A1 (en) * | 2013-12-06 | 2015-06-11 | 한명순 | Composition for preventing and improving diarrhea and oral syringe package using same |
EP3244905A4 (en) | 2015-01-18 | 2018-12-12 | Gavish-Galilee Bio Applications Ltd | Extracts of edible fungi enriched in vitamin d and compositions thereof and their use in the treatment of immune-related disorders |
EP3463467A4 (en) * | 2016-05-23 | 2020-01-01 | Orphaderm Limited | Biophotonic compositions comprising a fungal-derived chromophore |
KR20180093725A (en) | 2017-02-14 | 2018-08-22 | 강원대학교산학협력단 | Pharmaceutical composition for treating or improving sepsis containing lentinan |
CN108410944A (en) * | 2018-06-05 | 2018-08-17 | 郑州安图生物工程股份有限公司 | A kind of detection clostridium difficile culture medium and preparation method thereof |
TWI673058B (en) * | 2018-07-20 | 2019-10-01 | 金穎生物科技股份有限公司 | Ganoderma lucidum complex polysaccharide composition |
CN110403962A (en) * | 2019-09-04 | 2019-11-05 | 湖南宇山玉月农业科技有限公司 | A kind of application of Mycophyta in prevention and treatment chicken necrotizing enterocolitis |
CN110656053B (en) * | 2019-11-01 | 2021-04-13 | 广东省微生物研究所(广东省微生物分析检测中心) | Lepidium new strain and artificial cultivation method and application thereof |
FI130808B1 (en) * | 2021-02-19 | 2024-03-27 | Natural Resources Inst Finland Luke | Fungi-derived composition, its production process and uses |
IT202100029000A1 (en) | 2021-11-16 | 2023-05-16 | C I A M S R L | IMMUNOSTIMULANT COMPOSITIONS FOR PETS |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4163780A (en) * | 1977-03-30 | 1979-08-07 | Kirin-Seagram Limited | Ks-2-a |
US4247541A (en) * | 1978-05-12 | 1981-01-27 | Kirin Brewery Company Limited | Ks-2-b |
JPS5653101A (en) * | 1979-09-21 | 1981-05-12 | Kirin Brewery Co Ltd | Polysaccharide ks-2-d and its preparation |
CN1153179A (en) * | 1995-12-29 | 1997-07-02 | 中国科学院上海药物研究所 | Method for separation and purification of lentinan |
US5756318A (en) * | 1995-03-24 | 1998-05-26 | Amino Up Chemical Co., Ltd. | Polysaccharides and preparation thereof |
US7022685B2 (en) * | 1998-09-25 | 2006-04-04 | Biopolymer Engineering, Inc. | Very high molecular weight β-glucans |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0757761B2 (en) * | 1984-03-08 | 1995-06-21 | 株式会社林原生物化学研究所 | β-glucan, production method and use thereof |
EP0292601A1 (en) * | 1987-05-14 | 1988-11-30 | Noda Shokukin Kogyo Co., Ltd. | Anti aids drug extracted from lentinus edodes |
FR2631829B1 (en) * | 1988-05-30 | 1992-04-03 | Pasteur Institut | FUNGAL EXOPOLYSACCHARIDES HAVING IMMUNOSTIMULANT ACTIVITY, PROCESS FOR OBTAINING SAME AND THERAPEUTIC COMPOSITION CONTAINING THEM |
JPH0725802B2 (en) * | 1988-11-28 | 1995-03-22 | 味の素株式会社 | Process for producing curdlan or lentinan sulfate or salt thereof |
JP3522772B2 (en) * | 1991-05-21 | 2004-04-26 | 台糖株式会社 | Vaccine immunopotentiator |
NO20014256D0 (en) * | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Preparation of immunostimulatory compound |
DK1663103T3 (en) * | 2003-09-08 | 2012-01-30 | Genyous Biomed Internat Inc | Compositions of botanical extracts for cancer therapy |
-
2005
- 2005-07-15 EP EP05758000A patent/EP1774012A2/en not_active Withdrawn
- 2005-07-15 AU AU2005263329A patent/AU2005263329A1/en not_active Abandoned
- 2005-07-15 JP JP2007520666A patent/JP2008525311A/en active Pending
- 2005-07-15 WO PCT/DK2005/000498 patent/WO2006007848A2/en active Application Filing
- 2005-07-15 KR KR1020077003917A patent/KR20070057803A/en not_active Application Discontinuation
- 2005-07-15 CA CA2574060A patent/CA2574060C/en active Active
- 2005-07-19 TW TW094124419A patent/TW200607863A/en unknown
-
2007
- 2007-01-15 IL IL180713A patent/IL180713A0/en unknown
-
2011
- 2011-10-24 JP JP2011233448A patent/JP5502830B2/en active Active
-
2013
- 2013-10-15 JP JP2013214807A patent/JP5926226B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4163780A (en) * | 1977-03-30 | 1979-08-07 | Kirin-Seagram Limited | Ks-2-a |
US4247541A (en) * | 1978-05-12 | 1981-01-27 | Kirin Brewery Company Limited | Ks-2-b |
JPS5653101A (en) * | 1979-09-21 | 1981-05-12 | Kirin Brewery Co Ltd | Polysaccharide ks-2-d and its preparation |
US5756318A (en) * | 1995-03-24 | 1998-05-26 | Amino Up Chemical Co., Ltd. | Polysaccharides and preparation thereof |
CN1153179A (en) * | 1995-12-29 | 1997-07-02 | 中国科学院上海药物研究所 | Method for separation and purification of lentinan |
US7022685B2 (en) * | 1998-09-25 | 2006-04-04 | Biopolymer Engineering, Inc. | Very high molecular weight β-glucans |
Non-Patent Citations (20)
Title |
---|
"THE MERCK INDEX, 12th Edition", 1996, MERCK, article "Monographs 5462, 8112, 8699" * |
CHIHARA G ET AL: "FRACTIONATION AND PURIFICATION OF THE POLYSACCHARIDES WITH MARKED ANTITUMOR ACTIVITY, ESPECIALLY LENTINAN, FROM LENTINUS EDODES (BERK.) SING. (AN EDIBLE MUSHROOM)", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, AACR ANNUAL MEETING 2018; APRIL 14-18, 2018; CHICAGO, IL, vol. 30, no. 11, 1 November 1970 (1970-11-01), pages 2776 - 2781, XP008056561, ISSN: 0008-5472 * |
EUREKA BIOCHEMICALS: "Lentinan for injection", 2012, Retrieved from the Internet <URL:http://www.biochem.com.au/specs.htm> [retrieved on 20120106] * |
FRUEHAUF J P ET AL: "The effect of lentinan on production of interleukin-1 by human monocytes", IMMUNOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 5, no. 1, 1 October 1982 (1982-10-01), pages 65 - 74, XP023816066, ISSN: 0162-3109, [retrieved on 19821001], DOI: 10.1016/0162-3109(82)90037-6 * |
FUJII T. ET AL.: "Isolation and characterization of a new antitumor polysaccharide, KS-2, extracted from culture mycelia of Lentinus edodes.", J. ANTIBIOTICS, vol. XXXI, no. 11, 1978, pages 1079 - 1090 * |
JIN Y. ET AL.: "Antitumor activities of heteropolysaccharides of poria cocos mycelia from different strains and culture media.", J. CARBOHYDRATE RES., vol. 338, 2003, pages 1517 - 1521 * |
K ONOZAKI ET AL: "Human interleukin 1 is a cytocidal factor for several tumor cell lines", THE JOURNAL OF IMMUNOLOGY, vol. 135, no. 6, 1 December 1985 (1985-12-01), UNITED STATES, pages 3962 - 3968, XP055331005, Retrieved from the Internet <URL:http://www.jimmunol.org/content/135/6/3962.full.pdf> * |
MIZUNO M. ET AL.: "Contents of Anti-Tumor Polysaccharides in Certain Mushrooms and TheirImmunomodulating Activities", FOOD SCI. TECHNOLOGY, vol. 7, no. 1, 2001, pages 31 - 34 * |
PENG Y. ET AL.: "Structure and antibtumor activity of extracellular polysaccharide from mycelium", CARBOHYDRATE POLYMERS, vol. 54, 2003, pages 297 - 303 * |
RON N APTE ET AL: "The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 25, no. 3, 17 October 2006 (2006-10-17), pages 387 - 408, XP019447665, ISSN: 1573-7233, DOI: 10.1007/S10555-006-9004-4 * |
SONE Y. ET AL.: "Structures and antitumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum", AGR. BIOL. CHEM., vol. 49, no. 9, 1985, pages 2641 - 2653 * |
SUZUKI H. ET AL.: "Structural Characterization of the Immunoactive and AntiviralWater-solubilized Lignin in an Extract of the Culture Mediumof Lentinus edodes Mycelia (LEM)", AGRIC. BIOL. CHEM., vol. 54, no. 2, 1990, pages 479 - 487 * |
The GlycaNova Project: Lentinex vs other beta glucan products * |
TOGAMI M. ET AL.: "Studies in Basidiomycetes. I. Antitumor polysaccharide from Bagasse medium on which mycelia of Lentinus edodes (Berk.) Sing. had been grown.", CHEM. PHARM. BULL., vol. 30, no. 4, 1982, pages 1134 - 1140 * |
WANG H. ET AL.: "Lectins from mushrooms", MYCOL RES., vol. 102, no. 8, 1998, pages 897 - 906 * |
WASSER S.P. AND WEIS A.L.: "Medicinal properties of substances occurring in higher basidiomycetes mushrooms: current perspectives (Review)", INTL. J. MED. MUSHROOMS, vol. 1, 1999, pages 31 - 62 * |
YAP A T ET AL: "An Improved Method for the Isolation of Lentinan from the Edible and Medicinal Shiitake Mushroom,Lentinus edodes /Berk./ Sing./Agaricomycetideae/", INTERNATIONAL JOURNAL OF MEDICINAL MUSHROOMS, BEGELL HOUSE, GB, vol. 3, no. 1, 1 January 2001 (2001-01-01), pages 1 - 19, XP008082942, ISSN: 1521-9437 * |
ZHANG M. ET AL.: "Molecular weight and anti-tumor activity of the water soluble polysaccharide isolated by hot water and ultrasonic treatment from the sclerotia and mycelia of Pleurotus tuber-regium", CARBOHYDRATE POLYMERS, vol. 56, 2004, pages 123 - 128 * |
ZHENG X ET AL: "IMMUNE FUNCTION OF THE EXTRACELLULAR AND INTRACELLULAR POLYSACCHARIDES OF LENTINUS EDODES IN NORMAL MICE", ZHONGCAOYAO - CHINESE TRADITIONAL AND HERBAL D, TAINJIN ZHONGCAOYAO ZAZAHISHE, CN, vol. 16, no. 11, 1 January 1985 (1985-01-01), pages 494 - 497, XP008017834, ISSN: 0253-2670 * |
ZHOU W ET AL: "BIOLOGICAL ACTIVITY OF HYDROSOLUBLE EXOPOLYSACCHARIDE (HEP) FROM LENTINUS EDODES CL-2 BY SUBMERGED FERMENTATION", JUNWU XITONG - MYCOSYS, KEXUE CHUBANSHE, BEIJING, CN, vol. 16, no. 3, 1 January 1997 (1997-01-01), pages 202 - 207, XP008017985, ISSN: 1007-3515 * |
Also Published As
Publication number | Publication date |
---|---|
IL180713A0 (en) | 2007-06-03 |
AU2005263329A1 (en) | 2006-01-26 |
WO2006007848A2 (en) | 2006-01-26 |
JP5502830B2 (en) | 2014-05-28 |
CA2574060A1 (en) | 2006-01-26 |
CA2574060C (en) | 2019-06-25 |
JP2008525311A (en) | 2008-07-17 |
JP2012017347A (en) | 2012-01-26 |
WO2006007848A3 (en) | 2006-02-23 |
KR20070057803A (en) | 2007-06-07 |
JP5926226B2 (en) | 2016-05-25 |
TW200607863A (en) | 2006-03-01 |
JP2014005307A (en) | 2014-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7682615B2 (en) | Immune modulating compounds from fungi | |
CA2574060C (en) | Immune modulating compounds from fungi | |
US20100086647A1 (en) | Feed or food products comprising fungal material | |
US20090005340A1 (en) | Bioactive Agents Produced By Submerged Cultivation of a Basidiomycete Cell | |
JP5391282B2 (en) | Composition for promoting hematopoietic stem cell proliferation comprising fistula extract, reishi extract and mulberry extract | |
JP2004514403A (en) | Method for producing glucuronoxylomannan as a nutritional supplement from higher basidiomycete mushrooms and composition thereof | |
KR100945587B1 (en) | Method for preparing of fermented ginseng or fermented red ginseng containing ginsenoside metabolites fermented by cordyceps militaris having various physiological activity | |
TW201021816A (en) | Composition comprising a combination of an elder extract and a strain of L. paracasei, L. casei, L. bulgaricus or S. thermophilus | |
Mizuno | Development of an antitumor biological response modifier from Phellinus linteus (Berk. et Curt.) Teng (Aphyllophoromycetideae) | |
US11191793B2 (en) | Ganoderma lucidum polysaccharides composite composition | |
KR100340663B1 (en) | A method of preparing the antitumor and immuno-activity polysaccharide from the artificial cultivation of inonotus obliquus, and its use | |
TW201919657A (en) | Compositions and methods for enhancing immunity | |
KR20180042936A (en) | a composition comprising the mycelium culture medium from Schizophyllum commune as an active ingredient for preventing or treating liver disease and alleviating hangover | |
CN100417391C (en) | Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 for immune activation or prevention and treatment of cancer and the preparation method thereof | |
JP2003040785A (en) | Infection suppressing composition and food and drink containing the same | |
KR100589113B1 (en) | Utilization and processing of mushroom products fermented by lactic acid bacteria inhibiting helicobactor pylori and harmful enzymes in colon | |
KR20120019311A (en) | Composition for immunostimulation which comprises polysaccharide from fermented ginseng with phellinus linteus to enhance the immune function | |
WO2006126488A1 (en) | Cauliflower mushroom extract | |
KR100593533B1 (en) | Immune activity enhancing composition containing Felinus vaginal mycelium extract | |
KR20230030552A (en) | Composition for immunity enhancement comprising Artemisia gmelinii extract | |
JP2016098191A (en) | Antiallergic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070216 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20070827 |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1102609 Country of ref document: HK |
|
19U | Interruption of proceedings before grant |
Effective date: 20090204 |
|
19W | Proceedings resumed before grant after interruption of proceedings |
Effective date: 20100701 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BEKA HOLDING A/S |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BEKA HOLDING AS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GLYCANOVA AS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230331 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230811 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1102609 Country of ref document: HK |